Literature DB >> 27056794

Prevalence of Hepatotoxicity From Antituberculosis Therapy: A Five-Year Experience From South India.

Arunava Saha1, Margaret Shanthi F X1, Blessed Winston A1, Saibal Das2, Aniket Kumar1, Joy S Michael1, T Balamugesh1.   

Abstract

BACKGROUND: Antituberculosis (ATT) drug-induced liver injury (DILI) is a common and serious adverse effect of tuberculosis (TB) treatment. This retrospective study was carried out to study the prevalence of DILI among patients who had received anti-TB medications and to study some of the known risk factors responsible for causing DILI.
MATERIALS AND METHODS: This longitudinal descriptive study was performed to evaluate cases of DILI with predefined criteria. Patients of all ages, diagnosed and treated for smear positive pulmonary TB from January 1, 2008 to December 31, 2012 and those who came for regular follow-up were included in the study. Multiple logistic regression analysis was performed to determine the association of different risk factors and DILI. The confounders considered were age, sex, weight, body mass index, doses of drugs (fixed or per kg), ATT regimens (daily or intermittent), and treatment categories.
RESULTS: Of the 253 patients analyzed, 24 (9.48%) developed DILI. Associations of different risk factors were insignificant; including chronic alcohol consumption, hepatitis B infection, hepatitis C infection, HIV infection, and existing chronic TB.
CONCLUSION: DILI was not significantly associated with known risk factors in our settings.
© The Author(s) 2016.

Entities:  

Keywords:  antituberculosis (ATT) drugs; drug-induced liver injury (DILI); hepatotoxicity; liver function; pulmonary tuberculosis (TB)

Mesh:

Substances:

Year:  2016        PMID: 27056794      PMCID: PMC5932686          DOI: 10.1177/2150131916642431

Source DB:  PubMed          Journal:  J Prim Care Community Health        ISSN: 2150-1319


  23 in total

1.  Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1991-04

2.  Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.

Authors:  J N Pande; S P Singh; G C Khilnani; S Khilnani; R K Tandon
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

3.  Hepatotoxicity due to first-line anti-tuberculosis drugs: a five-year experience in a Taiwan medical centre.

Authors:  C-C Shu; C-H Lee; M-C Lee; J-Y Wang; C-J Yu; L-N Lee
Journal:  Int J Tuberc Lung Dis       Date:  2013-07       Impact factor: 2.373

4.  Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.

Authors:  Rohit Singla; Surendra K Sharma; Alladi Mohan; Govind Makharia; V Sreenivas; Brajesh Jha; Sanjeev Kumar; Pawan Sarda; Sarman Singh
Journal:  Indian J Med Res       Date:  2010-07       Impact factor: 2.375

5.  Hepatotoxicity of pyrazinamide: cohort and case-control analyses.

Authors:  Kwok C Chang; Chi C Leung; Wing W Yew; Tat Y Lau; Cheuk M Tam
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

6.  Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction.

Authors:  D Pessayre; M Bentata; C Degott; O Nouel; J P Miguet; B Rueff; J P Benhamou
Journal:  Gastroenterology       Date:  1977-02       Impact factor: 22.682

7.  Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?

Authors:  A Kumar; P K Misra; R Mehotra; Y C Govil; G S Rana
Journal:  Am Rev Respir Dis       Date:  1991-06

Review 8.  Drug induced hepatitis with anti-tubercular chemotherapy: challenges and difficulties in treatment.

Authors:  P V Kishore; S Palaian; R Paudel; P Mishra; M Prabhu; P R Shankar
Journal:  Kathmandu Univ Med J (KUMJ)       Date:  2007 Apr-Jun

Review 9.  Antituberculous drug-induced liver injury: current perspective.

Authors:  Harshad Devarbhavi
Journal:  Trop Gastroenterol       Date:  2011 Jul-Sep

10.  Factors associated with anti-tuberculosis medication adverse effects: a case-control study in Lima, Peru.

Authors:  Kocfa Chung-Delgado; Alejandro Revilla-Montag; Sonia Guillen-Bravo; Eduardo Velez-Segovia; Andrea Soria-Montoya; Alexandra Nuñez-Garbin; Wilmer Silva-Caso; Antonio Bernabe-Ortiz
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

View more
  3 in total

Review 1.  Safety implications of combined antiretroviral and anti-tuberculosis drugs.

Authors:  Maddalena Cerrone; Margherita Bracchi; Sean Wasserman; Anton Pozniak; Graeme Meintjes; Karen Cohen; Robert J Wilkinson
Journal:  Expert Opin Drug Saf       Date:  2019-12-06       Impact factor: 4.250

2.  Clinical features of adult patients with a definite diagnosis of central nervous system tuberculosis in an endemic country: A 13-year retrospective review.

Authors:  Suppachok Kirdlarp; Sirawat Srichatrapimuk; Sasisopin Kiertiburanakul; Angsana Phuphuakrat
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-09-10

3.  Co-administration of HAART and antikoch triggers cardiometabolic dysfunction through an oxidative stress-mediated pathway.

Authors:  R E Akhigbe; M A Hamed
Journal:  Lipids Health Dis       Date:  2021-07-05       Impact factor: 3.876

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.